CYRIB and breast cancer: Kaplan–Meier analysis showed that compared with FAM49B-negative BC patients, the survival rate of FAM49B-positive BC patients was significantly reduced (log-rank test, p < 0.05, HR = 1.874, 95% CI 1.045–3.362, Fig. 2E).